On December 10, 2025, the FTC announced that Teva Pharmaceuticals will “[r]emove.
. .  Over 200 Improper Patent Listings”
to improve generic competition.  The
Press Release states:

FTC investigation prompts Teva request for removal of patents
from Orange Book, paving the way for generic competition

After a challenge from the Federal Trade Commission, Teva
Pharmaceuticals…